Human Epidermal Growth Factor Receptor 2/neu Overexpression in Urothelial Carcinoma of the Bladder and Its Prognostic Significance: Is It Worth Hype?

Overview

Journal South Asian J Cancer

Specialty Oncology

Date 2016 Mar 5

PMID 26942140

Citations 9

Authors

Santosh Kumar

Omprakash Prajapati

Kim Vaiphei

Kalpesh Mahesh Parmar

A S Sriharsha

S K Singh

Affiliations

Soon will be listed here.

Abstract

Aims: In urothelial tumors of the urinary bladder, human epidermal growth factor receptor 2 (HER-2)/neu expression has been reported over 10 years, but there is no clear correlation between prognosis and recurrence rate. The present study evaluates prognostic implication of HER-2/neu expression.

Subjects And Methods: In this study, 100 formalin-fixed paraffin-embedded specimens of primary transitional cell carcinoma of the bladder were processed. HER-2/neu monoclonal antibody immunohistochemistry staining procedure used for the study.

Results: A total of 70 (70%) patients were positive for overexpression of HER-2/neu. HER-2/neu was positive in patients with 42 (70%) superficial tumor, 28 (70%) muscle invasive tumor, 41 (75.9%) high-grade tumor, 29 (63%) low grade tumor, 31 (68.9%) recurrent tumor, and 6 (66.6%) had positive lymph nodes.

Conclusions: Human epidermal growth factor receptor 2/neu over expression was not correlated with the tumor stage, lymphnode metastasis or recurrence of the disease. HER-2/neu overexpression was statistically insignificantly correlated with the differentiation grade (P < 0.161) as compared to previous studies. Future studies on HER-2 expression with chemo-sensitivity and efficacy of HER-2-targeted therapies in urothelial carcinomas is needed.

Citing Articles

GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis.

Plage H, Frericks A, Hofbauer S, Furlano K, Weinberger S, Rossner F BMC Urol. 2025; 25(1):37.

PMID: 39979991 PMC: 11841250. DOI: 10.1186/s12894-025-01704-y.

PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.

Plage H, Furlano K, Hofbauer S, Rossner F, Schallenberg S, Elezkurtaj S Int Urol Nephrol. 2024; .

PMID: 39680294 DOI: 10.1007/s11255-024-04319-8.

CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course.

Plage H, Furlano K, Neymeyer J, Weinberger S, Gerdes B, Hubatsch M BJUI Compass. 2024; 5(6):585-592.

PMID: 38873357 PMC: 11168773. DOI: 10.1002/bco2.354.

Human epidermal growth factor receptor 2/neu expression in urothelial carcinomas.

Soudamini A, Nalwa A, Choudhary G, Bharti J, Rao M, Elhence P Indian J Urol. 2024; 40(1):44-48.

PMID: 38314071 PMC: 10836454. DOI: 10.4103/iju.iju_287_23.

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.

Youssef M, Cavalu S, Hasan A, Yahya G, Abd-Eldayem M, Saber S Int J Mol Sci. 2023; 24(5).

PMID: 36902446 PMC: 10002602. DOI: 10.3390/ijms24055014.

References

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

Vollmer R, Humphrey P, Swanson P, Wick M, Hudson M . Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998; 82(4):715-23. DOI: 10.1002/(sici)1097-0142(19980215)82:4<715::aid-cncr15>3.0.co;2-0. View

Chakravarti A, Winter K, Wu C, Kaufman D, Hammond E, Parliament M . Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based.... Int J Radiat Oncol Biol Phys. 2005; 62(2):309-17. DOI: 10.1016/j.ijrobp.2004.09.047. View

Latif Z, Watters A, Dunn I, Grigor K, Underwood M, Bartlett J . HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003; 89(7):1305-9. PMC: 2394319. DOI: 10.1038/sj.bjc.6601245. View

Zhau H, Zhang X, Von Eschenbach A, Scorsone K, Babaian R, Ro J . Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990; 3(5):254-7. DOI: 10.1002/mc.2940030503. View

Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A, Syrjanen K . Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol. 1991; 20(3):238-42. DOI: 10.1159/000471706. View

Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P . Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996; 155(5):1784-8. View

Stern D . Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2001; 2(3):176-83. PMC: 138772. DOI: 10.1186/bcr51. View

Berger M, Greenfield C, Gullick W, Haley J, Downward J, Neal D . Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987; 56(5):533-7. PMC: 2001894. DOI: 10.1038/bjc.1987.238. View

10.

Alexa A, Baderca F, Zahoi D, Lighezan R, Izvernariu D, Raica M . Clinical significance of Her2/neu overexpression in urothelial carcinomas. Rom J Morphol Embryol. 2010; 51(2):277-82. View

11.

Carter P, Presta L, Gorman C, Ridgway J, Henner D, Wong W . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. PMC: 49066. DOI: 10.1073/pnas.89.10.4285. View

12.

Liedberg F, Anderson H, Chebil G, Gudjonsson S, Hoglund M, Lindgren D . Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?. Urol Oncol. 2008; 26(1):17-24. DOI: 10.1016/j.urolonc.2006.08.021. View

13.

Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T . Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep. 2007; 19(1):57-63. View

14.

Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T . Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol. 2002; 21(5):981-7. View